2023
A randomized clinical trial assessing the effect of automated medication-targeted alerts on acute kidney injury outcomes
Wilson F, Yamamoto Y, Martin M, Coronel-Moreno C, Li F, Cheng C, Aklilu A, Ghazi L, Greenberg J, Latham S, Melchinger H, Mansour S, Moledina D, Parikh C, Partridge C, Testani J, Ugwuowo U. A randomized clinical trial assessing the effect of automated medication-targeted alerts on acute kidney injury outcomes. Nature Communications 2023, 14: 2826. PMID: 37198160, PMCID: PMC10192367, DOI: 10.1038/s41467-023-38532-3.Peer-Reviewed Original ResearchConceptsAcute kidney injuryUsual care groupKidney injuryCare groupAcute Kidney Injury OutcomesAlert groupNon-steroidal anti-inflammatory drugsComposite of progressionHours of randomizationMedications of interestAldosterone system inhibitorsClasses of medicationsProton pump inhibitorsRandomized clinical trialsAnti-inflammatory drugsClinical decision support systemNephrotoxic medicationsHospitalized adultsDiscontinuation ratesCertain medicationsPrimary outcomeSubstantial morbiditySystem inhibitorsPump inhibitorsParallel group
2022
Deceased-Donor Acute Kidney Injury and Acute Rejection in Kidney Transplant Recipients: A Multicenter Cohort
Reese PP, Doshi MD, Hall IE, Besharatian B, Bromberg JS, Thiessen-Philbrook H, Jia Y, Kamoun M, Mansour SG, Akalin E, Harhay MN, Mohan S, Muthukumar T, Schröppel B, Singh P, Weng FL, Parikh CR. Deceased-Donor Acute Kidney Injury and Acute Rejection in Kidney Transplant Recipients: A Multicenter Cohort. American Journal Of Kidney Diseases 2022, 81: 222-231.e1. PMID: 36191727, PMCID: PMC9868058, DOI: 10.1053/j.ajkd.2022.08.011.Peer-Reviewed Original ResearchConceptsDe novo donor-specific antibodiesBiopsy-proven acute rejectionAcute kidney injuryNeutrophil gelatinase-associated lipocalinDe novo DSAGraft failurePrimary outcomeAcute rejectionKidney recipientsKidney injurySecondary outcomesAcute Kidney Injury Network criteriaClinical acute kidney injuryNovo donor-specific antibodiesSignificant associationKidney injury molecule-1Recipient alloimmune responsesUrinary IL-18Donor-specific antibodiesFirst posttransplant yearKidney transplant recipientsInjury molecule-1Gelatinase-associated lipocalinDeceased donor kidneysFine-Gray modelAngiopoietins as Prognostic Markers for Future Kidney Disease and Heart Failure Events after Acute Kidney Injury
Mansour SG, Bhatraju PK, Coca SG, Obeid W, Wilson FP, Stanaway IB, Jia Y, Thiessen-Philbrook H, Go AS, Ikizler TA, Siew ED, Chinchilli VM, Hsu CY, Garg AX, Reeves WB, Liu KD, Kimmel PL, Kaufman JS, Wurfel MM, Himmelfarb J, Parikh SM, Parikh CR. Angiopoietins as Prognostic Markers for Future Kidney Disease and Heart Failure Events after Acute Kidney Injury. Journal Of The American Society Of Nephrology 2022, 33: 613-627. PMID: 35017169, PMCID: PMC8975075, DOI: 10.1681/asn.2021060757.Peer-Reviewed Original ResearchConceptsCKD progressionHeart failureLower riskAngpt-1Highest quartileFuture kidney diseaseSetting of AKIAcute kidney injuryHeart failure admissionsHeart failure eventsProspective cohort studyMortality 3 monthsPlasma angiopoietinsKidney injuryCohort studySecondary outcomesEndothelial injuryMedian agePrimary outcomeKidney diseasePrognostic markerAngiopoietin-2AKIAngiopoietin-1Vessel destabilization
2021
Electronic health record alerts for acute kidney injury: multicenter, randomized clinical trial
Wilson FP, Martin M, Yamamoto Y, Partridge C, Moreira E, Arora T, Biswas A, Feldman H, Garg AX, Greenberg JH, Hinchcliff M, Latham S, Li F, Lin H, Mansour SG, Moledina DG, Palevsky PM, Parikh CR, Simonov M, Testani J, Ugwuowo U. Electronic health record alerts for acute kidney injury: multicenter, randomized clinical trial. The BMJ 2021, 372: m4786. PMID: 33461986, PMCID: PMC8034420, DOI: 10.1136/bmj.m4786.Peer-Reviewed Original ResearchConceptsAcute kidney injuryElectronic health record alertsKidney injuryPrimary outcomeMedical recordsYale New Haven Health SystemCare practicesGlobal Outcomes creatinine criteriaLarge tertiary care centerComposite of progressionDays of randomizationReceipt of dialysisPrespecified secondary outcomesTertiary care centerPatients' medical recordsSmall community hospitalNon-teaching hospitalsElectronic health recordsCreatinine criteriaUsual careSecondary outcomesAdult inpatientsKidney diseaseClinical centersWorse outcomes
2020
Uromodulin to Osteopontin Ratio in Deceased Donor Urine Is Associated With Kidney Graft Outcomes.
Mansour SG, Liu C, Jia Y, Reese PP, Hall IE, El-Achkar TM, LaFavers KA, Obeid W, Rosenberg AZ, Daneshpajouhnejad P, Doshi MD, Akalin E, Bromberg JS, Harhay MN, Mohan S, Muthukumar T, Schröppel B, Singh P, El-Khoury JM, Weng FL, Thiessen-Philbrook HR, Parikh CR. Uromodulin to Osteopontin Ratio in Deceased Donor Urine Is Associated With Kidney Graft Outcomes. Transplantation 2020, 105: 876-885. PMID: 32769629, PMCID: PMC8805736, DOI: 10.1097/tp.0000000000003299.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnimalsBiomarkersCells, CulturedDelayed Graft FunctionFemaleGlomerular Filtration RateGraft SurvivalHistocompatibility Antigens Class IIHumansKidneyKidney TransplantationMacrophagesMaleMiceMiddle AgedOsteopontinProspective StudiesRisk AssessmentRisk FactorsTime FactorsTissue DonorsUnited StatesUromodulinConceptsGraft failureGraft functionGraft outcomePrimary outcomeMajor histocompatibilityDeath-censored graft failureDeceased donor kidney transplantationCause graft failureImproved graft survivalRecipient graft outcomesKidney graft outcomeGlomerular filtration rateDeceased donor kidneysTime of procurementGraft survivalKidney transplantationDirection of associationDeceased donorsFiltration rateKidney qualityLower riskExtensive injuryDonor urineSimilar associationMouse macrophagesA Time-Updated, Parsimonious Model to Predict AKI in Hospitalized Children
Sandokji I, Yamamoto Y, Biswas A, Arora T, Ugwuowo U, Simonov M, Saran I, Martin M, Testani JM, Mansour S, Moledina DG, Greenberg JH, Wilson FP. A Time-Updated, Parsimonious Model to Predict AKI in Hospitalized Children. Journal Of The American Society Of Nephrology 2020, 31: 1348-1357. PMID: 32381598, PMCID: PMC7269342, DOI: 10.1681/asn.2019070745.Peer-Reviewed Original ResearchConceptsExternal validation cohortValidation cohortElectronic health recordsSevere AKIClinical risk stratification toolDevelopment of AKIHealth recordsRisk stratification toolInternal validation cohortLength of stayCharacteristic curveElectronic medical recordsNeonatal AKIInpatient mortalitySecondary outcomesHospital admissionPrimary outcomeHospitalized childrenCreatinine valuesMedical recordsStudy populationAKICohortChildrenPredictive variables
2019
Association of plasma-soluble ST2 and galectin-3 with cardiovascular events and mortality following cardiac surgery
Patel DM, Thiessen-Philbrook H, Brown JR, McArthur E, Moledina DG, Mansour SG, Shlipak MG, Koyner JL, Kavsak P, Whitlock RP, Everett AD, Malenka DJ, Garg AX, Coca SG, Parikh CR. Association of plasma-soluble ST2 and galectin-3 with cardiovascular events and mortality following cardiac surgery. American Heart Journal 2019, 220: 253-263. PMID: 31911262, PMCID: PMC7008086, DOI: 10.1016/j.ahj.2019.11.014.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryAgedBiomarkersBlood ProteinsCardiac Surgical ProceduresCardiovascular DiseasesCause of DeathCohort StudiesCoronary Artery BypassFemaleGalectin 3GalectinsHeart Valve Prosthesis ImplantationHumansInterleukin-1 Receptor-Like 1 ProteinMalePostoperative ComplicationsProspective StudiesVentricular RemodelingConceptsGal-3 levelsCardiovascular eventsCardiac surgerySignificant post-operative morbidityGalectin-3Gal-3 valuesPlasma soluble ST2Composite primary outcomePrimary composite outcomePost-operative morbidityCongestive heart failurePost-operative changesPotential clinical utilityRandom-effects modelPlasma sST2Soluble suppressionComposite outcomeHazard ratioProspective cohortTumorigenicity 2Heart failurePrimary outcomeMyocardial remodelingClinical covariatesClinical utilityThe Role of Volume Regulation and Thermoregulation in AKI during Marathon Running
Mansour SG, Martin TG, Obeid W, Pata RW, Myrick KM, Kukova L, Jia Y, Bjornstad P, El-Khoury JM, Parikh CR. The Role of Volume Regulation and Thermoregulation in AKI during Marathon Running. Clinical Journal Of The American Society Of Nephrology 2019, 14: 1297-1305. PMID: 31413064, PMCID: PMC6730516, DOI: 10.2215/cjn.01400219.Peer-Reviewed Original ResearchConceptsCore body temperatureBody temperaturePercent of runnersAcute tubular injuryPlasma copeptin concentrationsMajority of runnersContinuous core body temperatureAKIN criteriaDays postmarathonPrior marathonsTransient AKICopeptin concentrationsTubular injuryInjury biomarkersPrimary outcomeProspective cohortNephron damageNegative sodiumUrine microscopyVolume lossUrine sedimentAKIAbstractTextSweat sodiumCopeptin